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Bacteriophage p2 belongs to the most prevalent lactococcal phage group (936) responsible for considerable
losses in industrial production of cheese. Immunization of a llama with bacteriophage p2 led to higher titers
of neutralizing heavy-chain antibodies (i.e., devoid of light chains) than of the classical type of immunoglobu-
lins. A panel of p2-speciﬁc single-domain antibody fragments was obtained using phage display technology,
from which a group of potent neutralizing antibodies were identiﬁed. The antigen bound by these antibodies
was identiﬁed as a protein with a molecular mass of 30 kDa, homologous to open reading frame 18 (ORF18)
of phage sk1, another 936-like phage for which the complete genomic sequence is available. By the use of
immunoelectron microscopy, the protein is located at the tip of the tail of the phage particle. The addition of
puriﬁed ORF18 protein to a bacterial culture suppressed phage infection. This result and the inhibition of cell
lysis by anti-ORF18 protein antibodies support the conclusion that the ORF18 protein plays a crucial role in
the interaction of bacteriophage p2 with the surface receptors of Lactococcus lactis.
Lactococcus lactis is a gram-positive lactic acid bacterium
used for the manufacture of fermented dairy products (2). The
milk fermentation process is susceptible to infection by bacte-
riophages found in raw milk (3, 19, 32–34) or by induction of
prophages from lysogenic starter strains (19). The phage in-
fection results in lysis of the bacteria, leading to production
delays, variations in the taste and texture of the products, or
even complete failure of fermentation. To minimize economic
losses by phage infections, a variety of precautions are used
(35, 36). Lactococcal phages fall into three prevalent groups of
DNA homology, 936-, c2- and P335-like phages (32–34). Char-
acteristics of these phages include a double-stranded DNA
genome and a long noncontractile tail. The 936 and P335
groups have a small isometric head, while members of the c2
group have a prolate head.
We describe here the generation of phage-neutralizing
monoclonal single-domain antibody fragments (VHH) derived
from cameloid heavy-chain antibodies. In the blood of Cam-
elidae, a high proportion of the immunoglobulins consists of
homodimers of only heavy chains, devoid of light chains (17).
As described in this and other papers, it is possible to elicit
good immune response in camelids against complex protein
mixtures, phages, or even whole organisms (26). Genes encod-
ing VHH fragments that bind to these complex protein mix-
tures can be selected easily. In such libraries of binders, there
is a high probability of ﬁnding VHHs that block essential bio-
logical processes, mainly because of the long CDR3, which can
block active centers (27).
It was demonstrated that after immunization of a llama with
lactococcal bacteriophage p2 (936 group) the fraction of
heavy-chain antibodies contained about 10-fold higher neutral-
izing activity than conventional antibodies. We generated a
phage display library (31, 39) from which binding and neutral-
izing single-domain fragments were selected. Nanomolar con-
centrations of one of these VHHs efﬁciently neutralized lacto-
coccal bacteriophage p2 even in milk fermentation on a semi-
industrial scale (28). Here we show that the antigen open
reading frame 18 (ORF18) turned out to be a structural pro-
tein, and it was demonstrated that this protein is located at the
tip of the phage tail. The methods developed and the knowl-
edge generated by this study will lead ultimately to a better
understanding of the molecular mechanism of phage-host in-
teractions and to new effective ways to prevent viral infections
by application of llama antibody fragments.
MATERIALS AND METHODS
Selection and screening of lactococcal bacteriophage-speciﬁc single-domain
antibody fragments from a llama immune phage display library. Phage p2 was
puriﬁed, ampliﬁed, and concentrated as described previously (1). A llama was
immunized at days 0, 30, 58, and 86 with 3  10
7 PFU of L. lactis bacteriophage
p2 as described previously (10). The immune response was followed by titration
of serum samples in an enzyme-linked immunosorbent assay (ELISA) with
phage p2 coated at a titer of 10
10 PFU/ml in phosphate-buffered saline (PBS)
following the protocol described before (10).
Peripheral blood lymphocytes were isolated from a 150-ml blood sample,
taken 7 days after the last immunization, via a Ficoll-Paque gradient yielding
about 10
8 blood cells and comprising about 10
7 B cells. Total RNA (between 250
and 400 g) was extracted (5) and used for the preparation of random primed
cDNA (8), which served as the template for ampliﬁcation of the VHH genes with
oligonucleotide primers VH-2B, Lam-07 (priming to the short hinge region), and
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4531Lam-08 (long hinge speciﬁc) (10, 45). PCR was performed as described by De
Haard and colleagues (8).
The ampliﬁed products were digested with PstI and NotI and cloned in phage-
mid vector pUR5068, which is identical to pHEN1 (21) but contains a hexahis-
tidine tail for immobilized metal afﬁnity chromatography (20) and a c-myc-
derived tag for detection. Ligation and transformation were performed as
described previously (8).
The rescue with helper phage VCS-M13 and polyethylene glycol precipitation
was performed as described previously (30). Selections were done via the bio-
panning method (30) by coating of phage p2 (10
10 PFU/ml at round 1 and 10
9
PFU/ml at round 2) or via the in-solution selection method (18, 46) with in vitro
biotinylated phage (3  10
11 PFU/ml at the ﬁrst round and 3  10
10 PFU/ml at
the second round).
Soluble VHH was produced by individual clones as described previously (30).
Culture supernatants were tested in ELISA using immobilized phage p2; bound
VHH was detected with a mixture of the mouse anti-myc monoclonal antibody
9E10 (500 ng/ml) and anti-mouse horseradish peroxidase conjugate (DAKO;
4,000-fold diluted). Fingerprint analysis (46) with the restriction enzyme HinFI
(New England Biolabs) was performed on all clones.
Production of soluble VHH fragments by inducing 50-ml cultures and prepa-
ration of periplasmic fractions, which were used for ELISA experiments, were
done as described previously (8). DNA sequencing was performed at Baseclear
B.V. (Leiden, The Netherlands).
Production of VHH fragments in Escherichia coli and Saccharomyces cerevisiae.
For large-scale production (400 ml) in E. coli, the VHH-encoding gene fragments
were recloned via PstI/BstEII digestion in vector pUR5850 (Fig. 1A). This vector
is identical to phagemid vector pUR5068 but lacks gene 3 and contains an
additional carboxy-terminally located tag sequence of 15 amino acids, which
encodes an in vivo biotinylation signal (41). Alternatively, an E. coli production
vector was used encoding a different peptide sequence of ﬁve amino acid residues
(TAG) recognized by a monoclonal antibody instead of the c-myc tag.
After induction of VHH gene expression (8), a soluble protein fraction was
prepared by disruption of cells with a French press using a volume of 3.5 ml of
cell suspension in 0.1 mol/liter phosphate buffer (pH 7) in an FA-003 minicell at
20,000 lb/in
2 (American Instrument Company). This process was followed by
removal of the insoluble proteins via high-speed centrifugation (30 min at 13,000
 g at 4°C). The antibody fragments were puriﬁed from the lysate via their
hexahistidine tail using Talon column material (Clontech).
For secretion by S. cerevisiae, the fragments were recloned in episomal vector
pUR4547 (Fig. 1B), which is identical to previously described pUR4548 (10) but
does not encode any tag sequences. The host strain used, VWK18gal1, was a gal1
derivative of CEN.PK102-3A (MATa leu2 ura3) obtained by disruption of the
GAL1 gene by integration of the S. cerevisiae URA3 gene (40) at this locus.
Production on a 0.5-liter (shake ﬂasks) or a 10-liter scale was performed at BAC
B.V. (Naarden, The Netherlands) as described previously (43). The VHH frag-
ments were puriﬁed by ion-exchange chromatography with Mono-S-Sepharose
(Pharmacia) after concentrating the culture supernatant by ultraﬁltration. The
puriﬁcation yield was determined by measuring the optical density at 280 nm
(OD280), using the molar extinction coefﬁcients calculated from the encoded
amino acid sequence (program ProtParam-tools at www.expasy.ch). The purity
was analyzed on Coomassie-stained 15% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis gels.
Bihead molecules were produced in S. cerevisiae by introduction of an XhoI
site (instead of PstI) in the FR1-encoded primer and cloning of the PCR product
as an XhoI/BstEII fragment in an adapted version of episomal vector pUR4547.
This vector, pJS9, allows the insertion of another VHH gene downstream of the
ﬁrst one via digestion with PstI/HindIII.
The avidity of the puriﬁed VHH fragments was analyzed by gel ﬁltration using
a Superose 12 column combined with mass spectroscopy using matrix-assisted
laser desorption ionization–time of ﬂight mass spectrometry. In addition, a
bispeciﬁcity ELISA was performed according to the protocol described above
using p2 phage as coating. Detection was accomplished with a mixture of in vitro
biotinylated phage p2 (at 10
8 PFU/ml) and streptavidin-horseradish peroxidase
conjugate (DAKO; 1,000-fold diluted).
Determination of neutralizing capacity with plaque titration and small- and
large-scale neutralization assays. Plaque titration was performed according to
Terzaghi and Sandine (42). Indicator strains L. lactis subsp. cremoris LM0230
and C2 (7, 13) were used for titration of phages p2 and sk1.
The small-scale neutralization assay was performed by culturing L. lactis
LM0230 or C2 (1% inoculum overnight culture) in microtiter plates using 100 l
of sterilized semiskim milk containing 0.35% peptone (Difco), 0.35% yeast
extract (Difco), 1% glucose, 0.5% polymyxin B (Oxoid), 1% bromophenol red
(Sigma), and 10
3 PFU/ml of phage p2 in the presence of variable concentrations
of antibody fragments (in culture supernatant of E. coli, in llama sera, or as
puriﬁed antibody fragments). After overnight incubation at 30°C, growth of the
cells was visualized by the yellow color of the indicator, whereas a purple color
indicated repressed growth due to lysis of the cells.
The large-scale assay was performed by culturing in 20 ml LM17 medium at
30°C containing variable titers of phage p2 and concentrations of puriﬁed VHH
fragment or ORF18. The pH and OD600 of 1-ml samples were measured.
Characterization of recognized antigens. For immunoelectron microscopy,
150-mesh nickel grids were coated with Formvar, followed by carbon evapora-
tion. The grids, with their coated side up, were glow discharged for 30 s in air at
a pressure of about 0.1 torr. Thereafter, the grids were put two times for 10 s with
the coated side down on a droplet of distilled water, followed by ﬂoating for 10
min on a 20-l droplet of phage solution in 100 mM PBS (pH 7.2) with a titer of
10
10 PFU/ml. Excess phage suspension was removed with ﬁlter paper. All incu-
bations were performed at room temperature. Antibody fragments VHH#2 and
VHH#5 were diluted in 1% bovine serum albumin in PBS (BPBS) to a concen-
tration of about 20 g/ml and incubated for 15 min with the grids. After ﬁve
washes for 1 min by ﬂoating on droplets of BPBS, the different grids were placed,
sample side down, for 15 min on a 50-l droplet of rabbit anti-VHH polyclonal
antibody solution (50-fold dilution in BPBS). After washing with BPBS (as
FIG. 1. Plasmids used in this study. (A) Expression vector for large-
scale production of VHH fragments in E. coli. PlacZ  IPTG-inducible
promoter; pelB  signal sequence; myc and HIS6 encode tags; biot 
biotinylation site. (B) Expression/integration vector used to transform
S. cerevisiae and to express the various VHH fragments. Pgal7  ga-
lactose-inducible promoter, SUC2  invertase signal sequence, Tpgk
 the PGK terminator. LEU2 is the LEU2 gene behind a defective
promoter, which ensures, together with the 2 micron sequence, the
multicopy integration of this vector on the rDNA locus.
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polyclonal immunoglobulin G antibodies conjugated to 10-nm gold particles
(Aurion B.V., Wageningen, The Netherlands) diluted 10-fold in BPBS. After ﬁve
washes by ﬂoating in droplets of distilled water, the labeled phages were nega-
tively stained on a 100-l droplet of 2% aqueous uranyl acetate solution for
1 min, followed by removal of the excess stain with ﬁlter paper. After drying at
room temperature for 30 min, the labeled phages were examined with an EM420
transmission electron microscope (Philips) and micrographs were taken at an
acceleration voltage of 80 kV.
Epitope mapping was performed with the lambda gt11 system using the
method described by Mondelli and colleagues (37), in which random fragments
were generated from the genomic DNA of phage p2 and cloned in lambda gt11
(Promega). For screening of the expression library, approximately 5  10
4
plaques per plate (14 cm diameter) were analyzed. The inserts from phage clones
which bound to the VHH were ampliﬁed with gt11 forward and gt11 reverse
primers (Promega) and cloned into the pGEM-T easy vector (Promega), which
subsequently was sequenced with T7 and M13 reverse primers (Promega). The
epitope recognized was localized further by the pepscan method (15) using
overlapping 15-mer peptides derived from the major structural protein (msp)
gene product from phage sk1 as described previously (4).
For amino-terminal sequencing, 10
11 phage p2 particles were loaded on a 15%
polyacrylamide electrophoresis gel and blotted on a polyvinylidene diﬂuoride
membrane (ProBlott; Perkin-Elmer). The blot was stained with Coomassie bril-
liant blue, the band of interest was excised, and the amino-terminal sequence
determined with an LF-3000 Protein Sequencer (Beckman). The individual phe-
nylthiohydantoin amino acid derivatives from the Edman degradation were mon-
itored online and analyzed with a System Gold high-performance liquid chro-
matography system (Beckman).
Puriﬁcation of phage p2-encoded gene products expressed in E. coli. All the
primers used were based on the genomic sequence of sk1 (4). The gene encoding
the major structural protein (msp; ORF11) was ampliﬁed from phage p2 with
mcp 5 primer 5-GTC CTC GCA ACT GCC GTC TCC CAT GAA ATT AGA
TTA TAA TTC ACG TGA GAT-3 and mcp 3 primer 5-GAG TCA TTC TCG
ACT TGC GGC CGC TGA ATG GTC AGT TAC TGA AAC TCC TGC
GGT-3 using AmpliTaq Gold (Perkin-Elmer). The lysin gene (ORF20) was
obtained by ampliﬁcation with lys 5 primer 5-GTC CTC GCA ACT GCC GTC
TCC CAT GAA TAT AAC TAA TGC TGG CGT-3 and lys 3 primer 5-GAG
TCA TTC TCG ACT TGC GGC CGC TTT TTT AGC AAT GAT TGG TTT
GT-3. Finally, ORF18 was ampliﬁed with ORF18 5 primer 5-GTC CTC GCA
ACT GCC GTC TCC CAT GAC AAT TAA AAA CTT CAC GTT TTT CA-3
and ORF18 3 primer 5-GAG TCA TTC TCG ACT TGC GGC CGC TTT AAT
GAA GTA ACT TCC GTT ACC-3. All 5-end primers contain a BsmBI site
(shown in bold characters), which enables cloning in the NcoI site of vector
pET28a (Novagen), thereby creating the ATG start codon. The 3-end primers
have a NotI site (also in bold), which gives an in-frame fusion to the hexahistidine
tail when ligated to the corresponding site of pET28a. The PCR products were
puriﬁed from gel, digested with BsmBI and NotI, and after spin dialysis against
water, ligated to NcoI/NotI-digested pET28a and electroporated into E. coli
BL21-CodonPlus(DE3) cells (Novagen).
The ORF18-containing constructs were made from two individual PCR prod-
ucts and sequenced with the T7 and T7rev primers at BaseClear B.V. (Leiden,
The Netherlands), thereby excluding errors introduced by ampliﬁcation.
For production of the protein, transformants were grown at 37°C in 400 ml
2TY medium containing kanamycin (100 g/ml) until a late-log-phase culture
was obtained (OD600, approximately 0.9). The culture was induced by addition of
isopropyl--D-thiogalactopyranoside (IPTG; 1 mM), and growth was continued
for 4 h. Cells were harvested and disrupted in a French press as described
previously. The hexahistidine-tagged proteins were puriﬁed from the soluble
protein fraction with Talon (Clontech). Purity was analyzed on Coomassie-
stained polyacrylamide electrophoresis gels.
Afﬁnity measurements with surface plasmon resonance. Binding kinetics were
analyzed by surface plasmon resonance on a Biacore-3000 (Biacore) using a
surface-containing anti-TAG monoclonal antibody (approximately 9,000 re-
sponse units) covalently coupled to a CM5 chip (Biacore). A ﬁxed amount of
tagged antibody fragment VHH#5 was captured (120 and 300 response units),
and a variable concentration of puriﬁed ORF18 (between 30 nM and 5 M) was
injected at a ﬂow rate of 10 l/min. For an accurate determination of the off rate,
the low-density surfaces were used to avoid rebinding as could be concluded from
the monophasic dissociation. The on rate was determined from those measure-
ments, which showed no mass transport limitation.
RESULTS
Isolation of lactococcal bacteriophage p2-speciﬁc single-do-
main antibodies via phage display. A llama was immunized
with puriﬁed bacteriophage particles from L. lactis phage p2.
The antigen-speciﬁc immune response was followed by ELISA.
During these titrations, the total content of serum antibodies
was measured and no discrimination was made between the
response of the “classical” antibodies (i.e., containing a heavy
and a light chain) and the heavy-chain antibodies. After 3
weeks, the sera contained high titers of anti-p2 antibodies.
An important objective of this study was to identify VHH
fragments capable of preventing lactococcal phage infection by
monovalent binding to bacteriophage particles. In addition to
analyzing individual phage-binding antibody fragments in
ELISA, a phage microtiter plate neutralization assay was used
that permitted the analysis of large numbers of clones.
The performance of the assay was evaluated with immune
sera from the llama. The serum taken after the fourth immu-
nization had high titers of neutralizing antibodies, since com-
plete inhibition of infection at a phage titer of 10
5 PFU/ml was
obtained even at a serum dilution of 10
4. As expected, the
preimmune serum did not show neutralization. The heavy-
chain and classical double-chain antibodies were puriﬁed from
the postimmune serum and tested in serial dilutions. The long-
hinge-containing heavy-chain antibodies inhibited infection
with phage titers of 10
5 PFU/ml at an antibody concentration
of 620 ng/ml and the short-hinge heavy-chain antibodies at a
concentration of 960 ng/ml. The classical antibodies were less
efﬁcient and gave only partial neutralization at 9.5 g/ml. Fol-
lowing RNA isolation from B lymphocytes, the gene segments
encoding the VHHs were ampliﬁed and cloned to obtain a
phage display library with approximately 10
7 clones. After two
rounds of biopanning or selection with in vitro biotinylated L.
lactis phage p2, an increasing number of phage clones was
eluted, indicating successful selection. We used both selection
methods as antibodies with different binding characteristics are
selected by these methods (46). Several hundred clones sam-
pled from the unselected library and after both rounds of
selections were screened in an ELISA for the production of
p2-speciﬁc VHH fragments. A large fraction of clones bound
p2 positive, increasing from 60% after round 1 to 95% after
round 2, while no binding antibodies were found in 32 analyzed
clones from the unselected library. Furthermore, many differ-
ent phage p2-speciﬁc VHH-encoding clones were selected from
the library, as demonstrated by HinFI ﬁngerprint analysis (de-
tails not shown).
Identiﬁcation of phage p2 neutralizing antibodies with acid-
iﬁcation screenings assay. The culture supernatants of the
VHH-producing clones were tested in phage neutralization
assays, which showed that 6 out of 250 (2.4%) antibody frag-
ments analyzed inhibited phage infection completely and 36
out of 250 (14.4%) gave some degree of neutralization. It
should be noted that the most potent neutralizing VHH frag-
ments gave poor signals in the ELISA screening and would
have been missed if only a limited number of ELISA-positive
clones were analyzed with plaque-forming assays.
A panel of four nonneutralizing (VHH#1 to VHH#4) and
three neutralizing (VHH#5 to VHH#7) antibody fragments
with different HinFI ﬁngerprint patterns was studied in more
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the nonneutralizing VHH fragments have divergent sequences,
the neutralizing VHH fragments were very similar, indicating
that they all recognized the same epitope (Fig.2). The genes
encoding these VHH fragments were recloned in an episomal
vector designed for secretion of VHHs by S. cerevisiae (10, 46)
(Fig. 1B). The puriﬁed antibodies were diluted and tested in
the small-scale acidiﬁcation assay, in the plaque formation
assay, and in the ELISA. None of the four nonneutralizing
antibodies prevented infection of phage p2, although they have
a good antigen-binding capacity. The three neutralizing anti-
bodies completely inhibited phage infection (data not shown).
Efﬁciency of neutralization of VHH#5 and cross-reactivity
against other lactococcal phage groups. The ability to neutral-
ize phage was studied in more detail by regularly measuring the
pH of small-scale cultures (20 ml). A ﬁxed titer of phage (10
3
PFU/ml) was combined with one concentration (667 nM) of
the antibody fragment. The acidiﬁcation curve from the phage-
infected culture containing neutralizing antibody fragment
VHH#5 was indistinguishable from the noninfected control,
thus showing the normal drop of pH from 6.6 to 4.6 after 10 h
of cultivation. The infected culture combined with nonneutral-
izing fragments VHH#2 or VHH#3 showed no change in pH,
indicating that most lactococcal cells were lysed as a conse-
quence of phage infection (data not shown). Antibody frag-
ment VHH#5 prevented phage infection, even at concentra-
tions as low as 2.25 nM, as can be seen from the acidiﬁcation
and the cell density proﬁles of the cultures (Fig. 3A). Higher
phage titers (10
5 PFU/ml) could also be neutralized with
higher concentrations of antibody (Fig. 3B).
The cross-reactivity against other lactococcal phages was
investigated with the microtiter plate acidiﬁcation assay. Phage
sk1, a 936-like phage, was neutralized by VHH#5 as efﬁciently
as phage p2. Three nanomolar VHH#5 completely protected
the L. lactis host cells against phage infection, whereas a 10-
fold lower concentration (0.3 nM) failed to do so. Preimmune
llama serum showed no inhibition, while postimmune serum
also gave identical inhibition proﬁles for phages p2 and sk1
(phage neutralization at a serum dilution of 10
3, no inhibition
at 10
4). However, two members of the c2 group, phages Q38
and c2, were not neutralized by VHH#5, although postimmune
llama serum slightly inhibited infection at a 10-fold dilution.
Localization of recognized antigens with immunoelectron
microscopy and analysis of ﬁne speciﬁcity by epitope mapping.
Immunoelectron microscopy was performed to localize the
proteins recognized by the different VHH fragments on the
phage structure. Using immunogold labeling, it was shown that
both nonneutralizing antibodies VHH#2 (Fig. 4A) and
VHH#3 (not shown) bound to proteins located on the phage
capsid. In contrast, neutralizing antibody VHH#5 recognizes a
protein at the tip of the tail (Fig. 4B), which is the site involved
in host recognition during the phage adsorption process.
To identify the epitopes of the antibodies, a lambda gt11
expression library was constructed containing random genomic
DNA fragments from phage p2 approximately 50 to 250 bp in
length (37). Screening of approximately 100,000 lambda
plaques with VHH#2 resulted in the identiﬁcation of six pos-
itive clones. The inserts were subcloned, and sequencing dem-
onstrated that the antibody recognizes the carboxy-terminal
domain of the major structural protein (msp) of phage p2 (Fig.
5A). The epitope was localized further by pepscan analysis of
the 79-amino-acid peptide shared by the six gt11 clones (Fig.
5B) and was shown to consists of the sequence NGQLAPGV
YIVTFSA, corresponding to residues 271 to 285 of the msp.
This result also demonstrated, for the ﬁrst time, that the msp
(ORF11) of lactococcal 936-like phages is the predominant
protein of the capsid.
Upon screening of the gt11 expression library with neutral-
izing antibody VHH#5, no binding clones were obtained,
thereby prompting an alternative approach to identify the an-
tigen.
Characterization of antigen recognized by neutralizing an-
tibody by Western blot analysis and amino-terminal sequenc-
ing. To exclude a mechanism of neutralization based on avid
binding of multimerized antibody fragments leading to inacti-
vation of phage by aggregation, the valency of puriﬁed VHH#5
was determined by gel ﬁltration (16) and mass spectrometry
(Fig. 6). Gel ﬁltration revealed a molecular mass of 12.1 kDa
and mass spectroscopy 13.5 kDa for VHH#5, suggesting that
the antibody fragment indeed has a monomeric appearance. A
bihead fragment (6) containing head-to-tail-linked VHH#3
and VHH#2 (3-2) emerged from the column in a single peak
corresponding to the dimeric product (molecular mass of 26.6
kDa as determined with mass spectroscopy; data not shown).
FIG. 2. Amino acid sequences of nonneutralizing (A) and neutralizing (B) bacteriophage-speciﬁc VHH fragments. Residues are numbered in
accordance with Kabat et al. (23). The primer-encoded hinge region (long hinge) is also shown.
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phage p2 was coated to capture the bivalent antibody fragment
that could be detected with in vitro biotinylated p2 phages. No
response was obtained with VHH#5 when detection was per-
formed with biotinylated p2 phages, while positive signals were
found upon incubation with the anti-myc antibody, thereby
conﬁrming the monovalent character of this antibody frag-
ment. The bihead molecule 3-2, which was used as a positive
control in this assay, gave high signals with biotinylated p2
phage or anti-myc. From these experiments it was concluded
that the neutralizing capacity of VHH#5 is not caused by
aggregation of phage particles but that the nature of the phage-
derived antigen recognized by the antibody is crucial.
The structural protein recognized by neutralizing antibody
fragment VHH#5 was identiﬁed by Western blot analysis (Fig.
7). Here, phage sk1 was used instead of phage p2 because its
complete genomic sequence is available (4). A clear band was
visible on blot after incubation with VHH#5, and comparison
with a Coomassie stained blot showed that the recognized
antigen migrates somewhat faster than the msp. The amino
FIG. 3. Acidiﬁcation proﬁles and growth kinetics of phage-infected cultures as a function of the concentration of VHH#5. (A) Determination
of the minimal concentration of VHH to neutralize an infection of 10
3 PFU/ml phage p2 by measuring pH and OD600. (B) Growth kinetics
determined with OD600 for a culture containing 10
5 PFU/ml phage p2 and variable amounts of VHH.
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identical to the hypothetical gene product of ORF18 of phage
sk1. The molecular mass (30 kDa), as estimated from a gel,
suggests the presence of the complete ORF18 product (con-
taining 264 amino acid residues) in the bacteriophage particle.
To conﬁrm the observed speciﬁcity the ORF18 protein, the
major structural protein (msp) (ORF11) and lysin (ORF20)
expressed in E. coli, as well as complete phage sk1 particles,
were tested in Western blot assays with VHH#5 (Fig. 8). The
neutralizing antibody VHH#5 indeed recognized bacterially
expressed ORF18, which comigrated with the phage-bound
protein. As a control, fragment VHH#2 was included in the
experiment and as expected, this antibody reacted with the
mcp produced in E. coli and the phage-associated antigen. In
contrast, anti-mcp fragment VHH#3 also reacted with the bac-
terially expressed msp (containing the phage p2 gene) but
failed to recognize the corresponding product of phage sk1
(data not shown).
The afﬁnity of VHH#5 to puriﬁed ORF18 was determined
by analysis of the kinetics of the antibody-antigen interaction
using surface plasmon resonance. The association rate ka was
(3.49 	 0.51)  10
5 M
1 s
1, and the dissociation rate kd was
(4.82 	 1.09)  10
4 s
1, resulting in a KD of (1.40 	 0.21) 
10
9 M or 1.40 nM.
Competition assays with puriﬁed ORF18. Since binding of
an antibody fragment to ORF18 prevents infection, it was
hypothesized that this gene product might have an important
function during phage adsorption to the L. lactis host receptor.
This hypothesis was evaluated by adding E. coli-produced
ORF18 to phage-infected L. lactis cultures. We speculated that
the added ORF18 would compete with the ORF18 bound to
phage p2 particles for binding to the cellular receptor and
thereby prevent phage infection. At relatively high concentra-
tions of ORF18 (approximately 500 nM) and low titers of p2
phage (10
2 and 10
3 PFU/ml), phage infection of L. lactis cells
was completely prevented, while at lower concentrations of
ORF18, the phage infection process was only retarded (Fig. 9).
This addition of puriﬁed mcp had no effect on phage infection
(data not shown).
DISCUSSION
The vulnerability of lactic acid bacteria to phage attack still
is the biggest problem associated with industrial manufacture
of fermented dairy products (2). Phage p2 is a typical member
of the most frequently isolated lactococcal phage group, while
heavy-chain antibodies of Camelidae have a number of very
interesting properties and applications (10, 26, 43, 44, 46). We
decided to use these antibodies to develop a new powerful
route to neutralize phage and simultaneously to elucidate un-
known mechanisms of phage infection of lactic acid bacteria.
Evaluation of the neutralizing capacity of antibodies puriﬁed
from postimmune llama serum showed that the heavy-chain
antibodies inhibited phage infections more efﬁciently than clas-
sical antibodies. Overall, these data indicate that camelid
heavy-chain antibodies can eliminate viral infections efﬁciently,
FIG. 4. Immunoelectron microscopy with heavy-chain antibody fragments and 10-nm gold-labeled detection antibodies on bacteriophage p2.
(A) Phage detected with nonneutralizing VHH#2. (B) Phage recognized by neutralizing fragment VHH#5.
4536 DE HAARD ET AL. J. BACTERIOL.FIG. 5. Epitope mapping of anti-msp antibody fragment VHH#2. (A) Inserts of the VHH#2-recognized lambda gt11 clones (coded #1 to #6),
which encode a shared segment of the carboxy-terminal region of the major structural protein. Numbering has been done as in the deposited sk1
genomic sequence (GenBank accession number AF011378). The earlier observed differences (25) between the shown p2-derived sequence and the
sk1 sequence are indicated with boxes. (B) Pepscan results obtained with overlapping 15-mer peptides based on the shared sequence segment of
the lambda gt11 clones. The peak corresponds with the peptide having the sequence NGQLAPGVYIVTFSA and therefore represents the epitope
of VHH#2.
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usual long CDR3 regions of heavy-chain antibodies and func-
tional centers of proteins (9, 27). As has been found with
enzyme inhibiting heavy-chain antibodies, the extended CDR3
loops might protrude into clefts or cavities present on the
surface of viral or phage particles and block them (48, 49). A
large panel of different p2-speciﬁc VHH fragments was se-
lected from a phage display library and with a specially devel-
oped assay, a limited number of phage-neutralizing antibodies
were identiﬁed.
Sequence analysis revealed that all the antibody fragments
examined have the characteristics of the heavy-chain variable
region of single-domain antibodies (47). The four analyzed
ELISA-positive, but nonneutralizing, VHHs contain com-
pletely different sequences, and in particular, the variability
seems to be localized in the CDRs. The length of the CDR3 is
highly diverse, varying from 5 residues for VHH#2 to 15 res-
idues for VHH#1 and VHH#4. Antibodies VHH#2 and
VHH#3, which both react with the msp of p2, are also entirely
different in sequence, suggesting that both fragments might
recognize different epitopes. Indeed VHH#2 recognizes an
epitope shared by phages p2 and sk1, while VHH#3 reacts with
a distinct antigenic site, which exclusively occurs within the
mcp of phage p2. Alignment of the amino acid sequences using
previously published data (25) revealed that only four amino
acid differences exist between the msp of phage p2 and sk1.
Two of these changes are separated by only nine residues,
thereby making this region a prominent candidate for the
epitope of VHH#3. This area is located 15 residues upstream
of the epitope for VHH#2.
The three analyzed neutralizing antibodies VHH#5,
VHH#6, and VHH#7 are less variable in sequence and have a
CDR3 of the same length (14 amino acids), with only a few
differing residues within this important region. This indicates
that this group of antibodies recognizes the same antigen and
probably also an identical epitope.
The phage-inhibiting capacity of the antibody fragment
turned out to be dependent on the titer of the phage contam-
ination. When titers of 10
3 to 10
5 PFU/ml were tested, which in
a production plant would result in failed fermentation, an
antibody concentration as low as 2.25 nM gave complete neu-
tralization. This corresponds well to the measured afﬁnity (KD
 1.40 nM) of the antibody fragment. This means that the
proportion of antigen not bound by antibodies must be rather
high. This high efﬁciency may be explained in terms of com-
petition between antibody (with a high afﬁnity for the phage)
and cell-bound receptor (with a lower afﬁnity) for binding to
phage particles. The antibody concentration used, 2 nM, cor-
responds to 10
12 molecules/ml. From Western blot data, we
estimate that 10 copies of ORF18 protein are present per
phage particle, which implies 10
4 to 10
6 ORF18 molecules per
ml, while 10
12 VHH molecules are present with a high afﬁnity
(1.4 nM) for ORF18, whereas only about 10
10 ORF18 receptor
molecules are present per ml of bacterial cultures, with a mod-
erate afﬁnity for ORF18 (a few hundred nanomolar).
The antibody fragment prevents infection with the only
other 936-like phage examined (sk1) but failed to neutralize
two members of the c2 group, which is the second most prev-
alent lactococcal phage group and is genetically distinct from
the 936-like phages. This indicates that VHH#5 will only pro-
tect against 936-like phages. The efﬁcacy of fragment VHH#5
was evaluated in cheese production experiments using a 200-
liter vessel (28). The results were in line with those described
for the small-scale cultures; addition of VHH#5 to a ﬁnal
concentration of 7 or 70 nM completely neutralized phage
infections of 10
3 to 10
5 PFU/ml, and acidiﬁcation proﬁles iden-
tical to those of noninfected control were obtained. Using the
above-determined values for interactions and lysis and a set of
differential equations, we mimicked cell lysis by phages in the
presence and absence of VHH#5 and ORF18 at various con-
centrations of L. lactis cells. Depending on the number of
ORF18 proteins per phage cell, lysis can be predicted reason-
ably well (data not shown).
It was demonstrated that antibody fragment VHH#5 recog-
nizes the ORF18-encoded gene product, for which no function
was known (4). The antigen is a constituent of the tip of the
phage tail, as shown by immunoelectron microscopic studies.
FASTA analysis with the amino acid sequence of ORF18 gave
FIG. 6. Size exclusion chromatography of VHH#5. VHH#5 and a
mixture of marker proteins were analyzed on a Superdex 75 column,
and the measured OD214 was plotted against the retention time. The
peaks of the marker proteins (13.7, 25, 43, 67, and 2,000 kDa) are
shown.
FIG. 7. Speciﬁcity of neutralizing VHH#5 determined by Western
blot analysis. Phage sk1 was loaded (lane 1, 6  10
9 PFU; lane 2, 3 
10
10 PFU) onto a 15% gel, blotted, and incubated with VHH#5. The
other part of the gel (lane 3, 1  10
10 PFU; lane 4, 2  10
10 PFU) was
stained with Coomassie brilliant blue (CBB). The experimentally de-
termined amino-terminal sequence (ThrIleLysAsnPheThrPhePheSer
ProAsnSerThrGluPhe; the expected methionine as start residue has
been clipped off) of the recognized protein (arrows) corresponds to the
hypothetical gene product of ORF18. MW, molecular mass.
4538 DE HAARD ET AL. J. BACTERIOL.FIG. 8. Western blot analysis with phage p2-derived proteins expressed in E. coli or complete bacteriophage particles of sk1. The antibody
fragments VHH#2 and VHH#5 and postimmune llama serum (llama pAB blot) were used for detection. Puriﬁed ORF18, msp, lysin (lys), and a
bacterial extract of E. coli cells containing the expression vector used () and phage sk1 (
) were loaded. The hexahistidine-tagged proteins were
detected with anti-His monoclonal antibody (-His).
FIG. 9. Effect of ORF18 protein on infection as measured by acidiﬁcation and the kinetics of growth. (A) Two concentrations of ORF18 were
included in cultures of L. lactis C2 containing 10
2 PFU/ml bacteriophage p2. Infected and noninfected cultures were used as controls, while puriﬁed
msp was added to another infected culture. (B) Partial protection by addition of ORF18 against higher phage titers (10
3 PFU/ml) as measured by
the kinetics of growth (graph on the left). The dose-dependent neutralizing effect of ORF18 on cultures with phage titers of 10
2 PFU/ml was
studied in more detail with a new batch of puriﬁed ORF18 (growth curves on the right).
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phage sk1 and the gene 120 protein from Lactococcus phage
bIL170, which both belong to the 936 group.
Interestingly, some similarity was found with the baseplate
protein (orf bpp) from the temperate lactococcal bacteriophage
TP901-1, a P335-like phage (38) (Fig. 10). The homology with
orf bpp was found within the carboxy-terminal domain of the
gene product, of which the localization within the phage par-
ticle was established by immunogold labeling (22). Comparison
of the late regions of phages sk1 and lambda by gene size and
the predicted isoelectric points of their ORFs (4) previously
hinted toward a relationship of ORF18 with phage lambda
gene K, which belongs to the cluster of tail genes.
This conclusion is in agreement with the proposed function
of orf bpp from phage TP901-1. Knocking out almost the com-
plete gene of orf bpp in the lysogenic phage resulted in the
production of noninfectious phage particles (38). The authors
mentioned the possibility that this might be achieved by bind-
ing of orf bpp directly to the cells or indirectly by binding with
other proteins involved in the phage-host interaction. How-
ever, our competition experiments strongly suggest a direct
interaction.
The L. lactis-encoded receptor (pip) for c2-like phages has
been identiﬁed (7, 12–14) and was shown not to be responsible
for the entrance of 936-like (11) or P335-like (24) phages.
During FASTA analysis, no homology of ORF18 of phage p2
was found with genes from phage c2 (29). Since phage c2 binds
to another type of receptor, it can be assumed that the recep-
tor-binding proteins of phage c2 and p2 are different, explain-
ing why VHH#5 does not neutralize c2 infections. As a poten-
tial function of ORF18 has now been elucidated, this protein
can be used for the characterization of a Lactococcus receptor,
which is most likely to be a cell surface glycoprotein.
During this study, we have also proven that camelid anti-
bodies can be raised against proteins of a complete biological
entity, which opens the opportunity to develop protein arrays
based on these antibodies (26). Our electron microscopy stud-
ies showed that VHHs can be used to study protein complexes
in biological systems. Moreover, based on the knowledge
gained and the technologies developed in this study, the de-
velopment of VHHs that neutralize other prokaryotic or eu-
karyotic viruses can be envisioned.
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ADDENDUM
Following acceptance of the manuscript, Dupont et al. (K.
Dupont, F. K. Vogensen, H. Neve, J. Bresciani, and J. Joseph-
sen, Appl. Environ. Microbiol. 70: 5818–5828, 2004) also
showed that ORF18 is the receptor-binding protein of 936-like
lactococcal phages.
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